CR11303A - Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3 - Google Patents

Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3

Info

Publication number
CR11303A
CR11303A CR11303A CR11303A CR11303A CR 11303 A CR11303 A CR 11303A CR 11303 A CR11303 A CR 11303A CR 11303 A CR11303 A CR 11303A CR 11303 A CR11303 A CR 11303A
Authority
CR
Costa Rica
Prior art keywords
isoquinolinilo
isoindolinilo
histamine
antagonists
derivatives
Prior art date
Application number
CR11303A
Other languages
English (en)
Inventor
Dahui Zhou
Jonathan Laird Cross
Albert Jean Robichaud
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CR11303A publication Critical patent/CR11303A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion proporciona un compuetos de formula I y su uso para el tratamiento de un trstorno nerivioso central relacionado con, o que se ve afectado por el receptor de la histmamina-3
CR11303A 2007-09-12 2010-03-04 Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3 CR11303A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99363607P 2007-09-12 2007-09-12

Publications (1)

Publication Number Publication Date
CR11303A true CR11303A (es) 2010-03-18

Family

ID=40261509

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11303A CR11303A (es) 2007-09-12 2010-03-04 Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3

Country Status (25)

Country Link
US (1) US20090069300A1 (es)
EP (1) EP2200989A1 (es)
JP (1) JP2010539180A (es)
KR (1) KR20100054856A (es)
CN (1) CN101848896A (es)
AP (1) AP2010005202A0 (es)
AR (1) AR068423A1 (es)
AU (1) AU2008298926A1 (es)
BR (1) BRPI0817061A2 (es)
CA (1) CA2699384A1 (es)
CL (1) CL2008002726A1 (es)
CO (1) CO6300955A2 (es)
CR (1) CR11303A (es)
DO (1) DOP2010000079A (es)
EA (1) EA201000316A1 (es)
EC (1) ECSP10010025A (es)
MA (1) MA31699B1 (es)
MX (1) MX2010002760A (es)
NI (1) NI201000036A (es)
PA (1) PA8795701A1 (es)
PE (1) PE20090651A1 (es)
TN (1) TN2010000105A1 (es)
TW (1) TW200927114A (es)
WO (1) WO2009036144A1 (es)
ZA (1) ZA201001751B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
GB0907284D0 (en) 2009-04-28 2009-06-10 Queen Mary & Westfield College Compounds for inducing cellular apoptosis
PT2464645T (pt) * 2009-07-27 2017-10-11 Gilead Sciences Inc Compostos heterocíclicos fusionados como moduladores do canal de iões
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
US20130203756A1 (en) * 2010-10-29 2013-08-08 Jamie L. Bunda Isoindoline pde10 inhibitors
BR112013028886A2 (pt) * 2011-05-10 2016-08-09 Gilead Sciences Inc compostos heterocíclicos fundidos como moduladores dde canal de sódio
NO3175985T3 (es) 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
BR112014000267A2 (pt) 2011-07-04 2016-09-20 Bayer Ip Gmbh utilização de isoquinolinonas, isoquinolinedionas, isoquinolinetrionas e dihidroisoquinolinonas substituídas ou, em cada caso, sais das mesmas como agentes ativos contra o stress abiótico em plantas
WO2013076590A1 (en) 2011-11-23 2013-05-30 Oxygen Healthcare Research Pvt. Ltd Benzothiazine compounds as h3 receptor ligands
CN105254554B (zh) * 2014-07-14 2018-01-30 南开大学 一种制备异吲哚啉酮类化合物的方法
KR20220167298A (ko) * 2020-04-08 2022-12-20 레믹스 테라퓨틱스 인크. 스플라이싱을 조절하기 위한 화합물 및 방법
JP2023540270A (ja) * 2020-08-28 2023-09-22 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物およびその使用
CN115819347B (zh) * 2022-11-14 2024-08-30 暨明医药科技（苏州）有限公司 一种1-烷基-3-溴吡唑的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
EP1019047B1 (en) * 1997-05-01 2003-11-05 Eli Lilly And Company Antithrombotic agents
WO2002076925A2 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
US7381719B2 (en) * 2002-09-19 2008-06-03 Eli Lilly And Company Diaryl ethers as opioid receptor antagonist
ATE381566T1 (de) * 2004-05-14 2008-01-15 Millennium Pharm Inc Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
JP2008526895A (ja) * 2005-01-21 2008-07-24 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なイミダゾールおよびベンゾイミダゾール誘導体
CA2604920A1 (en) * 2005-04-15 2006-10-26 Elan Pharmaceuticals, Inc. Novel compounds useful for bradykinin b1 receptor antagonism

Also Published As

Publication number Publication date
WO2009036144A1 (en) 2009-03-19
NI201000036A (es) 2010-08-13
MA31699B1 (fr) 2010-09-01
US20090069300A1 (en) 2009-03-12
TN2010000105A1 (fr) 2011-09-26
CN101848896A (zh) 2010-09-29
AR068423A1 (es) 2009-11-18
CA2699384A1 (en) 2009-03-19
CL2008002726A1 (es) 2008-10-10
JP2010539180A (ja) 2010-12-16
EA201000316A1 (ru) 2010-10-29
BRPI0817061A2 (pt) 2015-03-24
MX2010002760A (es) 2010-04-01
ZA201001751B (en) 2010-11-24
EP2200989A1 (en) 2010-06-30
TW200927114A (en) 2009-07-01
CO6300955A2 (es) 2011-07-21
DOP2010000079A (es) 2010-03-31
AU2008298926A1 (en) 2009-03-19
PA8795701A1 (es) 2009-04-23
KR20100054856A (ko) 2010-05-25
ECSP10010025A (es) 2010-08-31
AP2010005202A0 (en) 2010-04-30
PE20090651A1 (es) 2009-05-28

Similar Documents

Publication Publication Date Title
CR11303A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3
CR11309A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonista de la histamnia-3
ECSP088620A (es) 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
CR7643A (es) Derivados de 1-heterociclialquil -3-sulfonilazaindol o azaindazol como ligandos de 5-hidroxitriptamina-6
HN2009001597A (es) 4-aril-1, 4-dihidro-1,6-naftiridinamidas sustituidas y su uso
HN2010001563A (es) Compuestos
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
CL2007001670A1 (es) Uso de compuestos derivados de amina para el tratamiento de un trastorno mediado por citoquinas.
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
SV2010003648A (es) Inhibidores del receptor de quimioquinas cxcr3
PA8790101A1 (es) Derivados de aminoalquilazol como antagonistas de histamina-3
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
UY30706A1 (es) Diaril, dipiridinil y arilpiridinil derivados y usos de los mismos
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
CR9733A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
PA8781601A1 (es) " derivados de azaciclilbenzamida como antagonistas de histamina-3
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
CR11828A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico
UY31637A1 (es) Farmacoforos duales-antagonistas muscarinicos de pde4
ECSP067096A (es) Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6
ECSP088930A (es) Derivados de benzoxazol y benzotiazol como ligandos de
CU20110020A7 (es) Compuestos de fenantrenona, composiciones y métodos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)